What's Happening?
ImmunityBio, Inc. has announced promising Phase 2 clinical results from its QUILT 3.078 study, which evaluates a chemotherapy-free combination immunotherapy regimen for recurrent glioblastoma (GBM). The study involves ANKTIVA® plus CAR-NK therapy, and
as of January 22, 2026, 19 out of 23 enrolled patients remain alive, with median overall survival not yet reached. The treatment has shown a manageable safety profile, with only three treatment-related serious adverse events reported. The study also observed a significant increase in absolute lymphocyte count (ALC), indicating improved immune competence among patients. These findings suggest a potential paradigm shift in GBM treatment, offering a durable and safe alternative to traditional chemotherapy.
Why It's Important?
The results from the QUILT 3.078 study are significant as they offer a new approach to treating glioblastoma, a highly aggressive and lethal brain cancer with limited treatment options. The ability to improve survival rates without the use of chemotherapy could transform the standard of care for GBM patients, who often experience severe side effects from traditional treatments. The increase in lymphocyte counts suggests that the therapy not only targets the tumor but also restores immune function, which is crucial for long-term disease control. This development could lead to more effective and less toxic treatment options for GBM patients, improving their quality of life and survival outcomes.
What's Next?
ImmunityBio plans to continue its research with randomized controlled trials in both first-line and second-line glioblastoma patients. These trials will further evaluate the efficacy and safety of the ANKTIVA and CAR-NK combination therapy. The company is also exploring the potential of this treatment approach in other cancers, aiming to develop therapies that bolster the immune system and reduce reliance on traditional chemotherapy. As the research progresses, it will be important to monitor the long-term outcomes and potential regulatory approvals for this innovative treatment.
Beyond the Headlines
The success of this study highlights the potential of immunotherapy in treating cancers that have been resistant to conventional treatments. It underscores the importance of understanding the immune system's role in cancer progression and the need for therapies that can restore immune competence. This approach could pave the way for new treatment paradigms in oncology, emphasizing the integration of immune-based therapies with traditional cancer treatments.
